

SDC, Figure S1




Figure 1: Flow chart of patients and ARV episodes enrolled in the study

BPAR: biopsy proven acute rejection;

ARV: acute rejection with v-lesions;

TCMRV: T-cell mediated rejection with v-lesions

AMRV: antibody-mediated rejection with v-lesions

DSA: Donor specific HLA-antibody;

Banff v-lesion: Banff scored lesion of intimal arteritis

SDC, Table S1

SDC, Table 1: The univariate and multivariate Cox-regression analysis of histological and clinical factors associated with graft loss at 10 years post transplantation

Univariate analysis (Overall ARV)									
Histological factors	HR	95% CI		p-value	Clinical factors	HR	95% CI		p-value
ptc (score 0-3)	1.2	1.2	2.0	<0.001	BPAR episodes (1-9)	1.4	1.2	1.6	<0.001
v (score 1-3)	1.3	1.0	1.8	0.07	For cause biopsy episodes (1-9)	1.2	1.1	1.4	0.003
cv (score 0-3)	1.6	1.0	3.0	0.11	Donor HLA-antibody class I	2.3	1.2	4.4	0.008
t (score 0-3)	1.2	0.9	1.7	0.18	PRA at transplantation (≥10%)	1.0	1.0	1.1	0.03
g (score 0-3)	1.4	1.0	2.7	0.33	The presence of DGF	2.0	1.2	3.4	0.03
C4d staining (score 0-3)	1.4	0.8	2.5	0.21	Broad HLA-mismatches (0-6)	1.2	1.0	1.5	0.06
ci/ct (score 0-3)	1.3	1.0	2.5	0.22	Responses to antirejection treatment [#] (1-3)	1.4	1.0	2.0	0.11
mm (score 0-3)	0.8	0.5	1.3	0.34	Cold ischemia time	1.0	1.0	1.1	0.14
ah (score 0-3)	1.0	0.8	1.4	0.74	Graft number (1-3)	1.3	0.8	2.1	0.37
cg (score 0-3)	1.0	0.7	1.4	0.91	Timing of AVR (early vs. late)	1.2	0.7	2.1	0.42
i (score 0-3)	1.0	0.7	1.5	0.98	Peak level of PRA (≥30%)	1.0	0.9	1.1	0.49
					Donor HLA-antibody class II	1.2	0.7	2.2	0.50
Multivariate analysis (Overall AVR)									
Histological factors	HR	95% CI		p-value	Clinical factors	HR	95% CI		p-value
ptc (score 0-3)	1.2	1.2	2.0	<0.001	Donor HLA-antibody class I	2.4	1.2	4.9	0.02
					BPAR episodes (1-9)	1.2	1.0	1.6	0.14
					For cause biopsy episodes (1-9)	1.1	0.9	1.4	0.29
					The presence of DGF	1.5	0.7	3.4	0.37
					PRA at transplantation (≥10%)	1.0	1.0	1.0	0.63

HR: hazard ratio; CI: conference intervals; Bx: allograft indicated biopsy;

[#]: the responses to anti-rejection were graded into complete-, partial- and no reversible levels

SDC, Table S2: Etiology of ESRD

	TCMRV (n=78)	sAMRV (n=37)	AMRV (n=33)	Overall (n=148)	Overall p-value
Glomerulonephritis N (%)	8 (10.3%)	2 (5.4%)	4 (12.1%)	14 (9.5%)	0.81
Hypertensive nephropathy N (%)	11 (12.9%)	2 (5.4%)	4 (12.1%)	17 (11.5%)	0.75
Diabetic nephropathy N (%)	22 (28.2%)	10 (27.0%)	7 (21.2%)	39 (26.4%)	0.95
Interstitial nephritis N (%)	7 (9.0%)	5 (13.5%)	1 (3.3%)	13 (8.8%)	0.59
Polycystic kidney disease N (%)	13 (16.7%)	2 (5.4%)	1 (3.3%)	16 (10.8%)	0.12
Other causes N (%)	9 (11.5%)	7 (18.9%)	11 (33.3%)	27 (18.2%)	0.49
Unknowing etiology N (%)	8 (10.3%)	9 (24.3%)	5 (15.2%)	22 (14.9%)	0.89